BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma

Drug combination therapies remain pivotal for the treatment of heterogeneous malignancies, such as glioblastomas. Here, we show a novel lethal interaction between Bcl-xL and c-myc inhibition accomplished by bromodomain protein inhibitors. Established, patient-derived xenograft and stem cell-like gli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Chiaki Tsuge, Bianchetti, Elena, Shu, Chang, Halatsch, Marc-Eric, Westhoff, M. Andrew, Karpel-Massler, Georg, Siegelin, Markus D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444687/
https://www.ncbi.nlm.nih.gov/pubmed/28418907
http://dx.doi.org/10.18632/oncotarget.16365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444687/
https://www.ncbi.nlm.nih.gov/pubmed/28418907
http://dx.doi.org/10.18632/oncotarget.16365

Ejemplares similares